About this report (Sumitomo Chemical and Sumitomo Pharmaceutical: Part II – CiRA, Dr. Yamanaka, and the undisclosed history of image-duplication concerns)

Section Heading

This report discloses our view on Sumitomo Chemical and Sumitomo Pharmaceutical: Part II – CiRA, Dr. Yamanaka, and the undisclosed history of image-duplication concerns. The document, based on the publication date of August 7, 2026, examines and explains the reliability of the research and approval review conducted by GCR and related organizations, including the headquarters, under long-standing industry-academia collaboration. It covers the credibility of references related to AmScheprei, the reliability of materials in collaboration with Kyoto University, and responses from legal and ethical perspectives.

Section 2 Heading

Going forward, we will take appropriate legal action against inaccurate or misleading information and ensure timely and appropriate information disclosure to shareholders and investors. Regarding GCR's views, we will re-examine the reliability of our materials and data and specify measures to enhance transparency. Regarding impact on shareholders and investors, we will monitor the investigation results and publication schedule and report progress as appropriate.